Cerevel Therapeutics Holdings, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 131.91 million compared to USD 104.29 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.67 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.63 USD | -0.27% |
|
-1.69% | -4.17% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.17% | 7.42B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- CERE Stock
- News Cerevel Therapeutics Holdings, Inc.
- Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024